Technology ID
TAB-1991

Truncated Methanocarba Adenosine Derivatives as A3 Adenosine Receptor Antagonists

E-Numbers
E-285-2008-0
Lead Inventor
Jacobson, Kenneth (NIDDK)
Applications
Therapeutics
Research Materials
Diagnostics
Therapeutic Areas
Immunology
Lead IC
NIDDK
ICs
NIDDK
Novel A3 adenosine antagonists available for licensing. A3 receptors are particularly highly expressed in inflammatory cells, making it a potentially desirable target for inflammatory diseases. This technology relates to highly specific antagonists and partial agonists of A3 adenosine receptors, which are negatively coupled to adenylate cyclase and have been broadly implicated in inflammation, cardiovascular disease, endocrine conditions and cancer. Further, A3 adenosine receptors have been implicated in asthma and glaucoma.
Competitive Advantages
  • There are four known subtypes of adenosine receptors (A1, A2A, A2B, and A3). All are positively or negatively linked to cAMP, but have different distributions and different therapeutic potentials. In particular, the use of A1 and A2 selective ligands has been limited by the ubiquity of expression of the receptors throughout the body and the resultant side effects. On the other hand, high levels of A3 receptor expression are limited to the CNS, testes, and the immune system. Thus, A3 receptors represent a potentially highly specific target for treating related diseases.

Request More Info

Licensing Contact:
Tong, Betty
tongb@niddk.nih.gov

Related Inventions

  • E-140-2008-1           TAB-2455
    A3 Adenosine Receptor Agonists to Treat Chemotherapy-induced Peripheral Neuropathy

Patents

  • US
    Provisional (PRV) 61/085,588
    Filed on 2008-08-01
  • Patent Cooperation Treaty
    (PCT) PCT/US2009/52439
    Filed on 2009-07-31
  • US Patent 8,796,291
    Filed on 2011-03-18

Publications

Collaborations

  • Licensing
  • Collaboration

License Status

  • Available for licensing.

Collaboration Description

  • The NIDDK, Laboratory of Bioorganic Chemistry is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize A3 adenosine receptor antagonists. Please contact Kenneth A. Jacobson, Ph.D. at kajacobs@helix.nih.gov or Marguerite Miller at Marguerite.Miller@nih.gov for more information.
Date Published